Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Investor Presentation (December 2019)
25 slides from Sanuwave Health's investor presentation, Dec 11, 2019
Slide 1: SANUWAVE: Healing today. Curing tomorrow.
SANUVAVE Healing today. Curing tomorrow. Creating a brighter future by providing novel and cost effective solutions, focused on societal needs with the sole purpose of bettering lives everywhere OTCQB: December 2019
Slide 2: Forward-Looking Statement Disclaimer
Forward-Looking Statement Disclaimer This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective.
Slide 3: SANUWAVE Health
SANUWAVE Health SANUWAVE Health (SNWV), Inc. is an emerging shockwave technology company focused on the ' JeomePace development and commercialization of patented noninvasive, high-energy, acoustic focused, shockwaves for the repair and regeneration of tissue, musculoskeletal and vascular structures.
Slide 4: Investment Highlights & Recent Developments
Investment Highlights & Recent Developments Accomplishments in 2018 Goals for 2019 * Hired Shri Parikh, President Healthcare * 110 US Placements ; 300 certified users * Received reimbursement tracking for DFU procedure * Reimbursement; finish with at least 10 million * Signed Premier Shockwave as th
Slide 5: A Leader in Shockwave Technology
A Leader in Shockwave Technology Development and Commercialization Patented, non-invasive devices for the repair and regeneration of: * Skin * Musculoskeletal tissue * Vascular structures Devices activate biologic signaling and angiogenic responses, producing: ¢ New vascularization _ | Immediate mic
Slide 6: Global Wound Care Market Overview
ee lobal Wound Care Market Overview US and worldwide wound prevalence Types of wound US prevalence Worldwide Healing time Estimated CAGR (m) prevalence (m) (days) (2007-16e) The Surgical wounds 67 1103 14 wounds is Bum wounds (hospitalised N increasing Traumatic wounds WA : Lace: $ N/A 12 prevalence
Slide 7: U.S. Wound Care Market Overview
U.S. Wound Care Market Overview US prevalence of all wounds U.S. prevalence of hard-to-heal wounds* (8 million pa) (3.2 million pa) Diabetic foot Venous ulcer me Diabetic foot 12% 18% Venous ulcer ulcer 15% 29% Arterial Ulcer 3% Arterial Ulcer Traumal > 8% surgical auns ape _ Pressure uler B Pressur
Slide 8: The dermaPACE System meets the market need
The dermaPACE® System meets the market need for better outcomes at lower cost SANUWAVE
Slide 9: The dermaPACE System positions SANUWAVE for large revenue potential
The dermaPACE® System positions SANUWAVE for large revenue potential across wound indications in the United States SANUWAVE Estimated at >$45 Billion Annual wound care costs in the United States* Pressure ulcers Diabetic foot ulcers (PUs) ?~$12Bn (DFUs) *~$15Bn Annual treatment Annual treatment cost
Slide 10: The dermaPACE System Positions for Continued Success; Market Drivers
The dermaPACE® Market Drivers Syste mM = Aging population * Clinical = Reach coe * Chronic illnesses practice/education* Funding pos it lions = Emerging middle = Innovation = Regulatory class environment oh pais Peflumand itl same ony . (Premium and mid-tier segments only) (Premium and mid-tier segm
Slide 11: Strategy to Capture Growth Opportunities
Strategy to Capture Growth Opportunities apture Grov = U.S. launch of dermaPACE = Sales coverage ramp up = Enhanced commercialization Broader Access Drive Global Expansion infrastructure Reduce Cost & Improve ’ ; = Emerging markets Efficiency P Deliver Economic Value * ‘Walueeudad elations and servi
Slide 12: Market Opportunity with The dermaPACE System
Market Opportunity with The dermaPACE® SYStChi===" U.S Market International Market * Diabetic Foot Ulcers - $4B+ market size. * Globally there are 382 million people living with diabetes and it is expected to reach 592 million by 2035, an increase of 55%. * dermaPACE is CE Marked and currently marke
Slide 13: The dermaPACE System: Treating Diabetic Foot Ulcers
The dermaPACE® System Treating Diabetic Foot Ulcers hes ® coo Robust closure with Non-invasive, convenient, Mechanism of action Cost-effective May be used as an adjunct extremely low recurrence and safe (MOA) allows : therapy rates Increased blood flow (perfusion) and improved vascularization (angio
Slide 14: U.S. Market Strategy
>10 million Pressure Sores 4s Million ALU 1.0 Million VLU 3.3 Million 19 Million OFU U.S. Market Strategy Expected Break Even Point fa eee eee eee 4 | \ Expand I indications to i drive increase in 1 usage. Expected | approval date: lili tie titi tie aetieetiaetioelieetiaetieelioetieetiaelioatiotion!
Slide 15: Growth Strategy
SANUWAVE Growth Strategy Seek relationships with qualified partners and JV/licensing agreements Address advanced wound care market - large and growing Y Domestic rollout of 2,000 placements; 500,000 treatments (DFU only) and greater than $100 million in revenue in 5 years v¥ With increased indicatio
Slide 16: Business Model Transformation
Business Model Transformation Transform from a product company to a provider of comprehensive value propositions and solutions that address the wound care patient pathway Current Business Model Future Business Model Competitive Strategy )» Portfolio of value-added Therapy ae d PACE® devi wound care
Slide 17: Global Clinical Studies
Global Clinical Studies Ql Q2 Q3 Q4 qi Q2 Q3 a4 Action Sites ——— — 2019 020 New AWC * VLU 12+ j i j i * Pressure Ulcer 12+ ' + ALU 12+ Vascularization/Perfusion/Dosing * Domestic/US 2 * Global 2 Surgical Incisions/Cosmetic * Domestic/US 1 Combination Therapy At any given time we are engaged in multi
Slide 18: Intellectual Property (IP) Organic Growth
Intellectual Property (IP) Organic Growth | a) «) cy US Patents Fore US Apps Fore SANUWAVE “J | 2006 2012 2018 US Patents 14 18 25 Foreign Patents 10 9 28 US Appl(s) i1 9 10 Foreign Appl(s) 2 10 19 [TOTAL 37 46 82 Percentage 24% Orthopedics, Orthopedics, Arthritis, Subject of Issued Patents bia tng
Slide 19: New Device Placements — Historical and Projection
New Device Placements (Includes International) — Historical and 2019 Projection 400 350 350 50 Units, International 300 ae 250 200 300 Units, US 150 140 30 Units, International 100 &VA 45 47 110 Units, 50 US non-VA/IHS 6 10 | = pocenent 0 — —_—— 2012 2014 2016 2018 2019 projection 2020 projection
Slide 20: Non-Medical Markets
Non-Medical Markets Addressable opportunities covered by Patents Energy Production Water = Advanced Fracking = Fracking Water Cleaning = Improved / Enhanced Oil = Industrial Water Cleaning Extraction Recovery * Drinking Water Cleaning Food Industry Industrial Biofilms = Preservation * Biofilm Destru
Slide 21: Wound Care Industry Valuations and Comparison
Company Name Ticker Symbol Market Cap (as of 12/1/19) Wound Care Integra Life Sciences Holding Corp. NASDAQ: IART $5.22B 7 Industry Valuations _ Convatec Group Ple LSE: CTEC $3.88 and Comparison Vericel Corporation NASDAQ: VCEL $847M Organogenesis NASDAQ: ORGO $512M <= °o c MiMedx Group Inc. OTC MKT
Slide 22: Select Financial Information
Select Financial Information Cash and Cash Equivalents - September 30, 2019 $402,656 Common Shares Outstanding 269M Warrants 30M Options Outstanding 33M Notes Payable - Due December 31, 2018 $7.1Mq) (1) Due to HealthTronics, Inc. as part of original 2005 purchase price SANUWAVE
Slide 23: Management Team
Management Team Kevin Richardson II, CEO and Chairman of the Board — Joined August 2005 a Joined the Company as chairman of the board of directors in August of 2005. Brings a broad array of financial knowledge for healthcare information:technology, financial services, business services and other ind
Slide 24: Why Invest in SANUWAVE
Why Invest in SANUWAVE® The dermaPACE® System received FDA Clearance on 12/28/2017 Internationally signed 20 new countries since 2018 Equipment Finance agreement signed in U.S. with NFS Seasoned Management team Advanced wound care market growing 5%+ YOY USA DFU market is over $4Billion annually Exec
Slide 25: SANUWAVE Health, Inc. Contact
SANUVVAVE Healing today. Curing tomorrow. To be viewed by the world as a diverse compassionate global family that provides positive impact on life and environment, one shock at a time. OTCQB: SNWV SANUWAVE Health, Inc. 3360 Martin Farm Road, Suite 100 Suwanee, GA 30024 info@sanuwave.com +1(770) 419-
SANUWAVE Health — Investor Presentation (December 2019) on 6ix